Fusidic Acid

Antibiotic Class:
Fusidane

Antimicrobial Spectrum:
Gram-positive: *Staphylococcus spp. C. difficile, C. perfringens, Peptostreptococcus spp., Propionibacterium acnes*
Gram-negative: *Neisseria spp.*
Other: *Mycobacterium spp.*

Mechanism of Action:
Inhibition of protein synthesis via interfering with elongation factor G

Pharmacodynamics: No data

Pharmacokinetics:
Cmax: 52.4 mg/L; Half-life: 9.8 (hr); Total Clearance: 21 ml/min; Volume of distribution: 0.3 L/kg; Table 2

Adverse Reactions:
Hematologic: granulocytopenia, thrombocytopenia
GI: hepatotoxicity, nausea, vomiting, abdominal pain, diarrhea,

Dosage:
Tablets: 250, 500mg
Suspension: 250mg/5ml
IV: 500mg vial

Adults: 250 – 500mg PO or IVq8 to q12 hours
Children: 12mg/kg up to 500mg IV q 12 hours or 20mg/kg/day divided q 8 hours

Disease state based dosing:
Renal failure: Dosing adjustments not necessary
Hepatic failure: No official recommendations exist, but avoidance in patients with severe liver disease may be warranted.

Contraindications/Warnings/Precautions:
Precautions: Use caution in patients with jaundice/hepatic dysfunction

Drug Interactions:
Fusidic acid is metabolized in the liver and CYP 450 enzyme interactions have been reported.
Ritonavir and Saquinavir: inhibition of metabolism and increased fusidic acid levels
Cholestyramine: binds fusidic acid and decreases bioavailability

Pregnancy: Category C: Risk unknown. Human studies inadequate.

Monitoring parameters:
Therapeutic: Culture and sensitivities, signs and symptoms of infection
Toxic: LFTs should be monitored in intravenous or prolonged therapy

Brand names/Manufacturer: